SecBot SecBot

ANIP drug pipeline

ANI PHARMACEUTICALS INC · 3 rated drugs
$68.55
−0.8% 1-day · Nov 20
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±3.6%
1-day, median of 2 events
IV rank
17
IV 38% · HV 32%
Rated drugs
3
1 bullish · 2 neutral
Phase 3 trials
1
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercially available since January 2022.

Cortrophin Gel repository corticotropin injection Updated Nov 16

What to watch

Cortrophin Gel is already approved and commercialized with no pending regulatory binary. The key near-term catalysts are commercial execution metrics: Q4 2026 Cortrophin revenue (expected early Feb 2027) will show whether the specialty pharmacy capacity constraints that slowed Q3 conversion have resolved, and whether the gout sales force expansion is gaining traction. The Egetis/EMCITATE acquisition acceptance period (Nov 20-Dec 18, 2026) is a separate corporate event that could affect ANIP's balance sheet and rare disease strategy.

Bull case
  • Cortrophin Gel is ANIP's largest and fastest-growing product: Q3 2026 revenue of $138.7M was up 36% YoY and 18% QoQ, with full-year 2026 guidance of $480M-$500M (38-44% YoY growth).
  • The drug is the only FDA-approved purified corticotropin product, competing in a market with limited alternatives (primarily Mallinckrodt's Acthar Gel), giving ANIP pricing power and a sticky chronic-use patient base.
  • ANI is expanding into the acute gout indication with a dedicated sales force, which could open a large new patient population and drive further growth.
Bear case
  • Cortrophin Gel revenue guidance was cut in August 2026 from $540M-$575M to $520M-$540M, and then narrowed further to $480M-$500M by November 2026, signaling demand or conversion headwinds.
  • Q3 2026 revenue conversion was slower than expected due to specialty pharmacy capacity constraints, suggesting operational bottlenecks that could persist.
  • The drug faces potential competition from Acthar Gel (Mallinckrodt), and any generic or biosimilar entry could erode pricing.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the EU (launched Germany May 2025) and US (commercially available October 27, 2026).

EMCITATE tiratricol Updated Nov 7

What to watch

The next catalyst is the ANI acquisition acceptance period (November 20 to December 18, 2026). If the deal closes, ANI will add an approved, first-in-class ultra-orphan drug with over $300M peak sales potential to its rare disease portfolio. If the deal fails (e.g., insufficient acceptance or regulatory issues), ANIP stock could re-rate lower given the acquisition premium was already priced in.

Bull case
  • EMCITATE is the first and only FDA- and EMA-approved treatment for MCT8 deficiency, a condition with no prior approved therapy, giving it a monopoly position in a defined ultra-orphan market.
  • Peak sales potential is estimated at over $300 million in the approved indication, and ANI's existing rare disease commercial infrastructure (Cortrophin Gel generated $347.8M in 2025) could accelerate the launch.
  • The Egetis board unanimously recommends the deal, ~42% of shares are already committed, and Egetis separately sold a Rare Pediatric Disease Priority Review Voucher for $190 million, improving deal economics.
Bear case
  • List price of ~$950,000/year for an ultra-rare disease with ~1,000 US patients creates significant payer access and reimbursement risk; commercial adoption may be slow.
  • ANI is taking on ~$560M in acquisition cost plus a $676M bridge facility, adding debt leverage to a company whose stock already trades near its 52-week low of $67.14.
  • Insiders (CEO, CFO, GC) have been consistently selling shares through 10b5-1 plans throughout Q3 2026, and multiple tracked institutional holders trimmed or exited positions in Q2 2026.
● neutral
Impact
PhaseApproved (Phase 4 SYNCHRONICITY data reported July 2026)
Time to marketAlready approved and marketed (FDA-approved September 2014 for DME; label expanded March 2025 for NIU-PS uveitis)

ILUVIEN fluocinolone acetonide Updated Jul 13

What to watch

ILUVIEN is a steady commercial asset within ANI's larger Rare Disease transition story. The positive July 2026 Phase 4 SYNCHRONICITY data supports the uveitis label expansion's real-world use, but the stock's bigger drivers are Cortrophin Gel growth and overall margin expansion. Watch quarterly sales trends for ILUVIEN against the $78M-$83M 2026 guidance.

Bull case
  • ILUVIEN is an already-approved, revenue-generating asset contributing $74.9M in 2025 net revenue, with 2026 guidance of $78M-$83M suggesting growth (source: ANI Q4 2025 earnings via fool.com).
  • The March 2025 FDA label expansion to chronic non-infectious uveitis (NIU-PS) opens a second addressable patient population beyond DME (source: globenewswire.com).
  • Positive Phase 4 SYNCHRONICITY data (July 13, 2026) met both co-primary endpoints, supporting real-world efficacy in uveitis and potentially driving physician adoption (source: yahoo.com).
Bear case
  • ILUVIEN is a niche product in DME, indicated only for patients previously treated with corticosteroids who did not have an intraocular pressure rise, limiting its addressable market vs. first-line anti-VEGF therapies like Eylea/Regeneron and Lucentis/Roche (source: healio.com).
  • Market access challenges (Medicare funding constraints for patient assistance programs) impacted Q1 2025 retina asset revenues; turnover in the ophthalmology sales team further pressured sales (source: SEC filing via sec.gov).
  • ILUVIEN is a mature product (approved since 2014) facing competition from other corticosteroid implants including ANI's own YUTIQ and AbbVie's Ozurdex, as well as newer anti-VEGF agents like Vabysmo (source: researchandmarkets.com).

Other drugs in filings and trials

no drug report yet
  • Yutiq 0.18 MG Drug Implant 1 trial

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Sep 28, 2026EMCITATEApproval−1.9%−1.9%
Jun 1, 2025ILUVIENApproval+5.4%+5.5%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Yutiq 0.18 MG Drug ImplantThe Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior SegmentPhase 3Completed10Mar 31, 2026